Therapeutic Potential of Catechin as an IKK-ß Inhibitor for the Management of Arthritis: In vitro and In vivo Approach.
J Pharm Bioallied Sci
; 15(4): 172-179, 2023.
Article
en En
| MEDLINE
| ID: mdl-38235046
ABSTRACT
Background:
Rheumatoid arthritis (RA) is associated with increased levels of cytokines, for instance, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and interleukin-1 (IL-1), which exhibit potent pro-inflammatory effects and are contributing factors to disease progression. A range of cytokines, cell adhesion molecules, and enzymes that are implicated in the debilitating effects of RA are transcribed by nuclear factor kappa.Objectives:
The purpose of this research was to characterize the efficacy of "catechin" as an IkappaB kinase-beta (IKK-ß) inhibitor in collagen-induced arthritis (CIA) model in mice, as IKK-ß is crucial in the transmission of signal-inducible NF-κß activation.Methods:
Arthritis was brought on in Bagg and Albino, but it is written BALB/c (BALB/c) male mice through subcutaneous immunization with bovine type II collagen on days 0 and 21. Catechin is given orally every day after the onset of the disease. Clinical evaluation of the prevalence and severity of the condition was done throughout the trial, and biochemical testing was done at the end (day 42).Results:
In vitro findings of the study demonstrated catechin as a potent inhibitor of IKK-ß with Half maximal Inhibitory Concentration (IC50) values of 2.90 µM and 4.358 µM in IKK-ß and NF-κß transactivation activity assay, respectively. Furthermore, catechin (dose range of 10-100 mg/kg, p.o.) was effective in reducing disease incidence and clinical signs in a dose-dependent manner, with an Effective Dose for 50% of the population (ED50) value of 79.579 mg/kg. The findings of this study demonstrate dose-dependent efficacy in terms of both disease severity (clinical scoring) and inflammatory markers (biochemical evaluation of the serum and joints).Conclusions:
IKK inhibitors are a prospective target for the creation of new therapeutics for arthritis and other inflammatory diseases because it has been suggested that this enzyme is crucial in the pathophysiology of RA. The finding of this study suggests that "catechin" represents a novel inhibitor of IKK-ß with promising anti-inflammatory activity.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
J Pharm Bioallied Sci
Año:
2023
Tipo del documento:
Article
País de afiliación:
India
Pais de publicación:
India